BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/380/0.1/20.12.24 | Market Closed - Bid/Ask 19:04:20 25/06/2024 BST | Pre-market 07:33:10 | |||
| 0.62 EUR | +3.33% |
|
0.6 | -3.23% |
| Current month | -46.09% | ||
| 1 month | -31.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 0.62 | +3.33% |
| 24/06/24 | 0.6 | -13.04% |
| 21/06/24 | 0.69 | +4.55% |
| 20/06/24 | 0.66 | -13.16% |
| 19/06/24 | 0.76 | +5.56% |
Real-time Boerse Frankfurt Warrants
Last update June 25, 2024 at 07:04 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VD3YF1 |
| ISIN | DE000VD3YF15 |
| Date issued | 11/04/2024 |
| Strike | 380 $ |
| Maturity | 20/12/2024 (178 Days) |
| Parity | 10 : 1 |
| Emission price | 2.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.69 € |
|---|---|
| Lowest since issue | 0.51 € |
| Spread | 0.04 € |
| Spread % | 6.35% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Warrants
- Warrant
